The North Carolina Business Court has denied a motion for summary judgment by the former president of a United Therapeutics Corp. subsidiary in a case involving allegations of trade secret misappropriation. The court held that the pharmaceutical company had taken reasonable steps to protect its trade secrets, extending beyond the typical three-year confidentiality period stipulated in the executive’s employment agreement. This decision ensures that the case will proceed to trial, maintaining the company’s stance that proprietary information was wrongfully transferred to a competitor.
Details of the court’s reasoning, as well as implications for corporate confidentiality practices, can be further explored in the original [article](https://www.law360.com/articles/1864987/ex-exec-can-t-escape-drug-co-s-trade-secret-suit), which provides a more comprehensive analysis of the proceedings.